Kenvue Inc. $KVUE Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 10.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 555,314 shares of the company’s stock after selling 64,738 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Kenvue were worth $11,689,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of KVUE. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after buying an additional 4,034 shares during the period. IFP Advisors Inc lifted its stake in shares of Kenvue by 25.3% during the first quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock valued at $369,000 after buying an additional 3,081 shares during the period. Vident Advisory LLC purchased a new position in shares of Kenvue during the first quarter valued at approximately $520,000. AG2R LA Mondiale Gestion D Actifs purchased a new position in shares of Kenvue during the first quarter valued at approximately $1,725,000. Finally, Czech National Bank lifted its stake in shares of Kenvue by 6.6% during the second quarter. Czech National Bank now owns 469,294 shares of the company’s stock valued at $9,822,000 after buying an additional 28,930 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 7.5%

Shares of NYSE:KVUE opened at $16.96 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The company has a market cap of $32.55 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.83. Kenvue Inc. has a 52 week low of $16.89 and a 52 week high of $25.17. The firm has a 50 day simple moving average of $20.77 and a 200 day simple moving average of $22.00.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is currently 112.16%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent analyst reports. Citigroup cut their price target on shares of Kenvue from $22.00 to $20.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 16th. UBS Group cut their price target on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, July 17th. Royal Bank Of Canada cut their price target on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Evercore ISI cut their price target on shares of Kenvue from $25.00 to $23.00 and set an “in-line” rating on the stock in a research note on Monday, September 8th. Finally, Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Tuesday, July 15th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.04.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.